个人简介

潘静，主任医师（所聘），博士研究生导师，医学/基础免疫学博士。曾获2021年度血液学十大研究进展、2024年度血液学研究十大进展、2025年度bat365正版唯一官网血液病医院（bat365正版唯一官网血液学研究所）协同创新奖。 院校引进人才，2026年加入院校，曾在北京高博医院任血液肿瘤免疫治疗科主任。同时担任北京医师协会儿童重症专科医师分会 常务理事、中国抗癌协会小儿肿瘤专业委员会专业委员、中国抗癌协会血液肿瘤专业委员会青年委员等学术职务。

主要研究内容

长期从事难治复发白血病CAR-T细胞免疫治疗及转化研究。聚焦CAR-T在r/r T-ALL临床转化困难及r/r B-ALL治疗后复发，在国际上首次提出并验证供者CD7 CAR-T治疗r/r T-ALL临床策略实现CAR-T临床转化突破；双表位CD5 CAR-T结合临床新策略挽救CD7 CAR-T治疗后抗原逃逸；序贯CD19/CD22 CAR-T临床新策略提高r/r B-ALL长期疗效。相关工作发表在Lancet Oncol（独立通讯）、J Clin Oncol（独立通讯）、Nat Med（第一/共同通讯）和Blood（第一/共同通讯）等期刊，高引4篇，写入6部国内外指南。

代表性成果

1. Jing Pan#*，Liping Zhao#，Yibing Zhang#，Samuel Seery, Yue Tan, Biping Deng, Lingling Shan, Zhuojun Ling, Fan Wu, Zelin Wang, Quangang Wang, Xinjian Yu, Qinlong Zheng, Xiuwen Xu, Ying Yuan, Zhenglong Tian, Yanlei Zhang, Shuixiu Peng, Alex H. Chang, Xiaoming Feng*. Donor-derived CD7 CAR T cells for pediatric and adult relapsed/refractory T-ALL/LBL: a phase 2 trial. Blood 146(23):2745–2757. (IF="23.1)

2. Jing Pan*, Yue Tan, Lingling Shan, Samuel Seery , Biping Deng, Zhuojun Ling, Jinlong Xu, Jiajia Duan, Zelin Wang, Kai Wang, Xinjian Yu, Qinlong Zheng, Xiuwen Xu, Guang Hu, Taochao Tan, Ying Yuan, Zhenglong Tian, Fangrong Yan , Yajing Han, Jiecheng Zhang，Xiaoming Feng *. Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 trial. Nature Medicine 31, 126–136 (2025). (IF="50.8," R)

3. Liping Zhao#, Chuo Li, Shiyu Zuo, Yajing Han, Biping Deng, Zhuojun Ling, Yanlei Zhang, Shuixiu Peng, Jinlong Xu, Jiajia Duan, Zelin Wang, Xinjian Yu, Qinlong Zheng, Xiuwen Xu, Ying Yuan, Zhenglong Tian, Kaiting Tang, Yibing Zhang, Qing Niu, Jiecheng Zhang, Alex H. Chang, Yuechen Luo*, Xiaoming Feng*, Jing Pan*. Autologous CD7 CAR-T cells generated without T cell pre-selection in pediatric patients with relapsed/refractory T-ALL: A phase I trial. Molecular Therapy 4;33(6):2753-2767. (IF="12.1)

4. Jing Pan#*, Kaiting Tang#, Yuechen Luo#, Samuel Seery, Yue Tan, Biping Deng, Feng Liu, Xiuwen Xu, Zhuojun Ling, Weiliang Song, Jinlong Xu, Jiajia Duan, Zelin Wang, Chunyu Li, Kai Wang, Yibing Zhang, Xinjian Yu, Qinlong Zheng, Liping Zhao, Jiecheng Zhang, Alex H Chang, Xiaoming Feng*. Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncology 24(11):1229-1241. (IF="41.6)

5. Yue Tan#, Lingling Shan#, Liping Zhao, Biping Deng, Zhuojun Ling, Yanlei Zhang, Shuixiu Peng, Jinlong Xu, Jiajia Duan, Zelin Wang, Xinjian Yu, Qinlong Zheng, Xiuwen Xu, Zhenglong Tian, Yibing Zhang, Jiecheng Zhang, Alex H. Chang*, Xiaoming Feng*, Jing Pan*. Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia. Journal of Hematology Oncology 16, 34 (2023). (IF="29.9," ESI, R)

6. Guoling Wang#, Xiaolei Sun#, Shiyu Zuo, Chuo Li, Qing Niu, Yonghui Xia, Yuan Meng, Min Liu, Zihao Fang, Yang, Yanyu Jiang, Sheng Wang, Haidong Cui, Huifang Huang, Erlie Jiang, Dongming Zhou, Qi Deng*, Jing Pan*, Xiaoming Feng*. Homogeneously high expression of CD32b makes it a potential target for CAR-T therapy for chronic lymphocytic leukemia. Journal of Hematology Oncology 14, 149 (2021). (IF="23.17)

7. Jing Pan#*, Yue Tan#, Guoling Wang#, Biping Deng, Zhuojun Ling, Weiliang Song, Samuel Seery, Yanlei Zhang, Shuixiu Peng, Jinlong Xu, Jiajia Duan, Zelin Wang, Xinjian Yu, Qinlong Zheng, Xiuwen Xu, Ying Yuan, Fangrong Yan, Zhenglong Tian, Kaiting Tang, Jiecheng Zhang, Alex H. Chang, Xiaoming Feng. Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial. Journal of Clinical Oncology 39, 3340-3351(2021). (IF="45.4," ESI, C100, R)

8. Jing Pan#*, Shiyu Zuo, Biping Deng, Xiuwen Xu, Chuo Li, Qinlong Zheng, Zhuojun Ling, Weiliang Song, Jinlong Xu, Jiajia Duan, Zelin Wang, Xinjian Yu, Alex H. Chang*, Xiaoming Feng*, Chunrong Tong*. Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL. Blood 135 (5): 387–391. (IF="23.629," ESI, C100, R)

9. Jing Pan#, Qing Niu, Biping Deng, Shuangyou Liu, Tong Wu, Zhiyong Gao, Zhaoli Liu, Yue Zhang, Xiaomin Qu, Yanlei Zhang, Shaohui Liu, Zhuojun Ling, Yuehui Lin, Yongqiang Zhao, Yanzhi Song, Xiyou Tan, Yan Zhang, Zhihui Li, Zhichao Yin, Bingzhen Chen, Xinjian Yu, Ju Yan, Qinlong Zheng, Xuan Zhou, Jin Gao, Alex H. Chang*, Xiaoming Feng*, Chunrong Tong*. CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia. Leukemia 33, 2854–2866 (2019). (IF="8.665," ESI, C100, R)

10. Jing Pan#, Junfang Yang, Biping Deng, Xiaojie Zhao, Xian Zhang, Yuehui Lin, Yanan Wu, Zhengling Deng, Yanlei Zhang, Shaohui Liu, Tong Wu, Peihua Lu, Daopei Lu, Alex H. Chang*, Chunrong Tong*. High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients. Leukemia 31(12):2587-2593(2017). (IF="10,023," F1000, C100, R)